Delocamten
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Delocamten
- Molecular weight
- 377.39
- Structure (SMILES)
- Cc1ccc(F)c([C@@H]2Nc3[nH]c(=O)n(C4CCOCC4)c(=O)c3C[C@@H]2F)c1
- bms 986435
- Bms-986435
- BMS-986435
- delocamten
- Delocamten
- delocamten [INN]
- DELOCAMTEN [USAN]
- delocamten inn
- delocamten usan
- myk 224
- MYK 224 [WHO-DD]
- myk 224 who dd
- Myk-224
- MYK-224
- pyrido 2 3 d pyrimidine 2 4 1h 3h dione 6 fluoro 7 2 fluoro 5 methylphenyl 5 6 7 8 tetrahydro 3 tetrahydro 2h pyran 4 yl 6s 7s
- Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 6-fluoro-7-(2-fluoro-5-methylphenyl)-5,6,7,8-tetrahydro-3-(tetrahydro-2H-pyran-4-yl)-, (6S,7S)-
- CAS registry numbers
- 2417411-02-8
- ChEMBL ID
- CHEMBL6068426
- InChIKey
- NPPSFOUMKWFJKX-HOTGVXAUSA-N
- PubChem compound IDs
- 146586175
- FDA ingredient codes (UNII)
- IE5886BN8T
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -camten
- Condition
- Cardiomyopathy, Hypertrophic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000538
- Subject identifier
- D002312
- Condition
- Heart Failure
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition identifier
- EFO_0000538
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005045
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
Trial references
- NCT05556343
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 76.12
- Calculated partition coefficient (ALogP)
- 2.38
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 27
- Molecular formula
- C19H21F2N3O3
- Monoisotopic mass
- 377.15509786
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (9)
- A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants
- A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
- A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
- A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
- A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants
- Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
- Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
In development for (2)
- Heart failure Phase 1
- Hypertrophic cardiomyopathy Phase 2